<DOC>
	<DOCNO>NCT02854163</DOCNO>
	<brief_summary>The investigator propose open label pragmatic clinical laboratory study design investigate , detail , clinical molecular effect Interleukin 17 ( IL-17 ) inhibition IL-17 secukinumab , neutrophil function vitro ex vivo . As secondary , exploratory objective , investigator utilise fact secukinumab administer 20 patient Psoriatic Arthritis ( PsA ) investigate whether relationship vitamin D status response secukinumab , respect efficacy adverse event . The result secondary exploratory analysis inform design large , definitive study .</brief_summary>
	<brief_title>Effect Secukinumab Treatment Psoriatic Arthritis</brief_title>
	<detailed_description>Phase : Phase 2 Clinical Trial Investigational Medicinal Product ( CTIMP ) Sample Size : 25 patient plus 10 healthy control enrol total . Study Population : Patient treatment group : 25 patient active psoriatic arthritis ( fulfil Classification Criteria Psoriatic Arthritis [ CASPAR ] criterion ) affect ≥2 peripheral joint ( swollen tender ) respond least two standard Disease-modifying antirheumatic drug ( DMARDs ) . Healthy control group : 10 healthy control blood sample ( match gender patient within 5 year mean age within gender subgroup ) . Number Sites : 1 - Rheumatology clinic Aintree University Hospital , Liverpool Study Duration : 24 month total 12 month therapy , 12 month stagger enrolment laboratory investigation Description Agent/Intervention Secukinumab 150mg/300mg subcutaneous injection weekly first 4 week 150mg subcutaneous injection 4 weekly 11 month . Primary Aim : The primary aim determine molecular effect IL-17 inhibition IL-17 secukinumab neutrophil phenotype , lifespan , function production IL-17 . Secondary Aims : 1 . To determine neutrophil life span function associate vitamin D concentration VDR receptor expression PsA patient , 2 . To explore whether vitamin D concentration VDR expression influence neutrophil lifespan function PsA patient treatment secukinumab . Exploratory Aims : 1 . To evaluate clinical response patient psoriatic arthritis , treat secukinumab use Psoriasis Area Severity Index ( PASI 75 ) American College Rheumatology response criterion ( ACR20 ) , 2 . To identify whether vitamin D status accord winter summer season level VDR expression associate skin joint response infection patient treat secukinumab PsA , assess use PASI 75 90 , ACR20 response report infection adverse event . 3 . To evaluate safety patient treat secukinumab term adverse event ( AE ) , serious adverse event ( SAE ) , infection serious infection , malignancy , acute injection site reaction potential immunogenicity 12 month . Study Design : Screening eligibility Patient group : Patients attend routine rheumatology assessment screen suitability study . Eligible patient , base diagnosis PsA ( meet CASPAR criterion peripheral joint involvement ) , approached determine willing participate . Patients randomly assign secukinumab treatment usual DMARD treatment base 4:1 ratio . Healthy Control Group : Healthy control match gender within 5 year mean patient age ( assessed patient group ) recruit National health Service ( NHS ) university staff . Baseline assessment Baseline assessment Vitamin D , VDR , Neutrophil function ACR20 , Body Surface Area ( BSA ) , PASI 75 90 , Nail Psoriasis Severity Index ( NAPSI ) , Psoriatic Arthritis Response Criteria ( PSARC ) , EuroQol five dimension questionnaire ( EQ5D ) &amp; Health Assessment Questionnaire ( HAQ ) . 1 . Secukinumab Arm 3 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D , HAQ 6 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D , HAQ 9 month - assessment Vitamin D , VDR , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D HAQ 12 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D , HAQ 13 month ( final follow visit ) - pregnancy test , Full Blood Count ( FBC ) , LFTs , serum creatinine body temperature measurement . Then exit study 2 . DMARD arm ( control group evaluate potential seasonal variability ) 3 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D , HAQ 6 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI 75 AND 90 , NAPSI , PSARC , EQ5D , HAQ 9 month - assessment Vitamin D , VDR , ACR20 , PASI , NAPSI , PSARC , EQ5D HAQ 12 month - assessment Vitamin D , VDR , Neutrophil function , ACR20 , PASI , NAPSI , PSARC , EQ5D , HAQ 13 month ( final follow visit ) - pregnancy test , FBC , LFTs , serum creatinin body temperature measurement . Then exit study 3 . Healthy Control Group : Blood sample obtain baseline assessment Vitamin D , VDR neutrophil function . Analysis Plan : Phase 1 : - Measure change 3 month , 6 12 month assessment ( baseline ) neutrophil function , DMARD control group secukinumab arm . - Explore use longitudinal model whether change outcome variable differ 2 treatment arm first 6 month , adjust confound variable . Phase 2 : - Measure vitamin D concentration , VDR 3 month , 6 month , 9 month 12 month . - Model fluctuation vitamin D , season dependant estimate maximal . - Compare treatment response time point treatment low vitamin D concentration ( winter time ) high vitamin D concentration ( summer time ) . - Assess whether difference neutrophil function , ACR20 , PASI 75 90 response NAPSI correlate change vitamin D , use longitudinal model</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients Patients active psoriatic arthritis ( fulfil CASPAR criterion ) affect ≥2 peripheral joint ( swollen tender ) respond least two standard DMARDs All meet CASPAR criterion diagnosis PsA , Be rheumatoid factor anticyclic citrullinated peptide ( antiCCP ) negative screening , Have prior exposure biologic therapy , Not receive parenteral glucocorticosteroids 6 week prior baseline assessment , If take oral glucocorticoid remain stable dose &lt; 10mg throughout study change dose 6 week prior baseline assessment , If take methotrexate DMARDs remain stable dose throughout study change dose therapy 6 week prior baseline assessment Patients Active chronic infection include mycobacterium tuberculosis , HIV , hepatitis B C Absence active psoriatic arthritis Patients start antiTNF therapy treat PsA Pregnancy plan pregnancy 1 . WOCBP unwilling unable ot use acceptable method avoid pregnancy study duration plus timeframe specified section 5.2.5 . 2 . Women pregnant breastfeed 3 . Sexually active fertile men use effective birth control partner WOCBP . Malignancy Chest Xray chest MRI evidence ongoing infectious malignant process obtain within 3 month prior Screening evaluate qualified physician . Patients hyponatraemia nephrotic syndrome Previous exposure secukinumab biologic drug directly target IL17 IL17 receptor . Patients take highpotency opioid analgesic ( e.g . methadone , hydromorphone , morphine ) . Use investigational drug and/or device within 4 week randomization period 5 halflives investigational drug , whichever longer . Significant comorbidity , opinion investigator , would impact ability participate Any change dose oral glucocorticosteroids DMARDS prior 6 week prior Baseline visit use i.v . intramuscular intraarticular glucocorticosteroid last 6 week prior enrolment visit . Patients previously treat TNFα inhibitor ( investigational approve ) . History hypersensitivity study drug excipients drug similar class . Previous treatment celldepleting therapy include limited antiCD20 investigational agent ( e.g . CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 ) . Active ongoing inflammatory disease PsA might confound evaluation benefit secukinumab therapy . Underlying metabolic , hematologic , renal , hepatic , pulmonary , neurologic , endocrine , cardiac , infectious gastrointestinal condition opinion Investigator immunocompromise patient and/or place patient unacceptable risk participation immunomodulatory therapy . Significant medical problem disease , include limited following : uncontrolled hypertension ( ≥ 160/95 mmHg ) , congestive heart failure ( New York Heart Association status class III IV ) , uncontrolled diabetes . History clinically significant liver disease liver injury indicate abnormal liver function test ( LFT ) aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , serum bilirubin . The Investigator guide follow criterion : 1 . Any single parameter may exceed 2 x upper limit normal ( ULN ) . A single parameter elevate include 2 x ULN rechecked soon possible , case , least prior enrollment/randomization , rule laboratory error . 2 . If total bilirubin concentration increase 2 x ULN , total bilirubin differentiate direct indirect react bilirubin . In case , serum bilirubin exceed 1.6 mg/dL ( 27 μmol/L ) . History renal trauma , glomerulonephritis , patient 1 kidney , serum creatinine level exceed 1.5 mg/dL ( 132.6 μmol/L ) . Screening total white blood cell ( WBC ) count &lt; 3 000/μL , platelet &lt; 100 000/μL neutrophil &lt; 1 500/μL hemoglobin &lt; 8.5 g/dL ( 85 g/L ) . Active systemic infection last 2 week ( exception : common cold ) prior randomization . History ongoing , chronic recurrent infectious disease evidence tuberculosis accord local practice/guidelines ) positive QuantiFERON TBGold test TBSpot Test ( indicate Section 4.1 Table 61 ) . Patients positive test may participate study work ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis . If presence latent tuberculosis establish treatment accord local country guideline must initiate . Known infection human immunodeficiency virus , hepatitis B hepatitis C Screening randomization . History lymphoproliferative disease know malignancy history malignancy organ system within past 5 year ( except basal cell carcinoma actinic keratoses treat evidence recurrence past 3 month , carcinoma situ cervix noninvasive malignant colon polyp remove ) . Use Vitamin D contain supplement . Inability unwillingness undergo repeat venepuncture ( e.g . poor tolerability lack access vein ) . Patients receive live vaccine within 4 week prior plan randomisation must exclude . Healthy Controls 10 healthy control blood sample . The healthy control recruit staff University Liverpool Aintree University hospital take take precede 6 month , immunosuppressive agent include systemic corticosteroid whose health otherwise good . There equal balance male female . Matching biologic DMARD control require . The healthy control provide one sample blood neutrophil study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Secukinumab</keyword>
	<keyword>Neutrophils</keyword>
	<keyword>Vitamin D</keyword>
</DOC>